BioInvent International AB (publ) (LON:0H22)
31.45
+1.50 (5.01%)
At close: Nov 20, 2025
LON:0H22 Revenue
BioInvent International AB had revenue of 3.32M SEK in the quarter ending September 30, 2025, a decrease of -73.98%. This brings the company's revenue in the last twelve months to 244.85M, up 533.73% year-over-year. In the year 2024, BioInvent International AB had annual revenue of 44.69M, down -37.47%.
Revenue (ttm)
244.85M SEK
Revenue Growth
+533.73%
P/S Ratio
8.43
Revenue / Employee
2.15M SEK
Employees
114
Market Cap
162.97M GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |